Supplement mimics DASH diet to fight hypertension in african americans

NCT ID NCT05145309

Not yet recruiting Prevention Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether potassium magnesium citrate, a supplement that provides key nutrients from the DASH diet, can lower blood pressure in African Americans with pre- or stage 1 hypertension. The study will enroll 45 participants and measure blood pressure over 24 hours. If successful, it could offer a simple way to prevent or manage high blood pressure in a group that often faces higher risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Potassium magnesium citrate
What this could lead to: If it works, this supplement could offer a simple, diet-like way to lower blood pressure in African Americans, potentially reducing their risk of heart disease.
What could go wrong: This is a small, early-phase trial with only 45 participants, so results may not apply broadly. The supplement may not lower blood pressure as hoped, and side effects like stomach upset are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.